Biotechnology firm Rigel Pharmaceuticals, Inc. is focused on developing and delivering innovative therapies that improve the quality of life for individuals suffering from hematologic disorders and cancer. Its portfolio includes Tavalisse, an oral spleen tyrosine kinase inhibitor designed for adult patients dealing with chronic immune thrombocytopenia, and Rezlidhia, a non-intensive monotherapy intended for adult patients coping with relapsed or refractory acute myeloid leukemia carrying a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Rigel also has a product in its pipeline, Fostamatinib, which has progressed to Phase III clinical trials and is proposed for the treatment of warm autoimmune hemolytic anemia. Moreover, Fostamatinib has finished the FOCUS Phase III clinical trial, which was conducted to ascertain its potential for treating hospitalized high-risk COVID-19 patients, and is currently undergoing Phase II/III clinical trials to determine its feasibility in treating COVID-19 patients admitted to a hospital. Alongside partner Eli Lilly and Company, the firm is developing an interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program that are both at different stages of clinical development. Additionally, Rigel has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. With its headquarters located in South San Francisco, California, Rigel Pharmaceuticals, Inc. was founded in 1996.
Rigel Pharmaceuticals's ticker is RIGL
The company's shares trade on the NASDAQ stock exchange
They are based in San Francisco, California
There are 51-200 employees working at Rigel Pharmaceuticals
It is rigel.com
Rigel Pharmaceuticals is in the Healthcare sector
Rigel Pharmaceuticals is in the Drug Manufacturers - Major industry
The following five companies are Rigel Pharmaceuticals's industry peers: